“In addition, in the 28-day, 3- and 6- or 9-month repeat dose toxicity studies, there were no iberdomide-related electrocardiographic findings or CNS-related clinical observations in monkeys up to 1 mg/kg or CNS-related clinical observations in rats up to 50 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗
Why that species
All metabolites formed in human hepatocytes were also formed in rat or monkey
“All metabolites formed in human hepatocytes were also formed in rat or monkey, the 2 animal species used for nonclinical safety testing.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Surrogate molecule
No surrogate; the clinical compound (CC-220) was tested
“Study Title: A 4-Week Nasogastric Gavage Toxicity Study of CC-220 in Cynomolgus Monkeys with a 4-Week Recovery Period”
✓ VerifiedFDA multi-discipline review, p. 61Source ↗
Species: general tox
Rat and cynomolgus monkey (28-day, 3-, 6- or 9-month studies)
“In addition, in the 28-day, 3- and 6- or 9-month repeat dose toxicity studies, there were no iberdomide-related electrocardiographic findings or CNS-related clinical observations in monkeys up to 1 mg/kg or CNS-related clinical observations in rats up to 50 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗
Species: DART
Rabbit (fertility/FEED) and rat and rabbit (EFD)
“The effects of iberdomide on fertility and embryo-fetal development were evaluated in fertility and early embryonic development (FEED) study in rabbits and embryo-fetal development (EFD) studies in rats and rabbits.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Species: carcinogenicity
Not conducted
“No carcinogenicity studies have been conducted with iberdomide.”
✓ VerifiedFDA multi-discipline review, p. 77Source ↗
Surrogate used in
No surrogate used; clinical compound (CC-220) tested
“Study Title: A 4-Week Nasogastric Gavage Toxicity Study of CC-220 in Cynomolgus Monkeys with a 4-Week Recovery Period”
✓ VerifiedFDA multi-discipline review, p. 61Source ↗